Literature DB >> 2502891

Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia.

S Di Giovanni1, G Valentini, P Carducci, P Giallonardo.   

Abstract

Serum beta 2-microglobulin (beta 2M) was measured in 22 patients with B chronic lymphocytic leukemia (CLL) and in 15 healthy age-matched control subjects. The patients were allocated in stages in accordance with the Rai and Binet systems. The beta 2M mean value in the CLL group was significantly higher than in the control group. There was a positive correlation between beta 2M and the clinical stage in both staging systems. The mean serum levels of beta 2M in stages A, B and C of Binet's system showed statistical differences while in stage A they did not differ from those found in the control group. No correlation was demonstrated between beta 2M and the peripheral lymphocyte concentration. A slight correlation was found between beta 2M and the degree of bone marrow lymphocyte infiltration, whereas a stronger relationship was observed when the type of infiltration (non-diffuse versus diffuse) was considered. Patients with bulky disease had mean beta 2M values much higher than the others.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502891     DOI: 10.1159/000205558

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

Review 1.  Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.

Authors:  Tom Butler; J G Gribben
Journal:  Blood Rev       Date:  2010-04-15       Impact factor: 8.250

2.  The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.

Authors:  Ravin Garg; William Wierda; Alessandra Ferrajoli; Lynne Abruzzo; Sherry Pierce; Susan Lerner; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

3.  Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Neil E Kay; Timothy G Call; Sara J Achenbach; James R Cerhan; Susan L Slager; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-06-04       Impact factor: 6.998

Review 4.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

Review 5.  Chronic lymphocytic leukemia: treatment options for patients with refractory disease.

Authors:  Marina Motta; William G Wierda; Alessandra Ferrajoli
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

6.  The spectrum of use of rituximab in chronic lymphocytic leukemia.

Authors:  Alessandra Tedeschi; Eleonora Vismara; Francesca Ricci; Enrica Morra; Marco Montillo
Journal:  Onco Targets Ther       Date:  2010-11-26       Impact factor: 4.147

7.  Increased serum level of alpha-2 macroglobulin and its production by B-lymphocytes in chronic lymphocytic leukemia.

Authors:  Regina Michelis; Lama Milhem; Evleen Galouk; Galia Stemer; Ariel Aviv; Tamar Tadmor; Mona Shehadeh; Lev Shvidel; Masad Barhoum; Andrei Braester
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

8.  Functional proteomic analysis of seminal plasma proteins in men with various semen parameters.

Authors:  Rakesh Sharma; Ashok Agarwal; Gayatri Mohanty; Rachel Jesudasan; Banu Gopalan; Belinda Willard; Satya P Yadav; Edmund Sabanegh
Journal:  Reprod Biol Endocrinol       Date:  2013-05-11       Impact factor: 5.211

9.  Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks.

Authors:  André F Rendeiro; Christian Schmidl; Jonathan C Strefford; Renata Walewska; Zadie Davis; Matthias Farlik; David Oscier; Christoph Bock
Journal:  Nat Commun       Date:  2016-06-27       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.